Reuters logo
BRIEF-Retrophin Q4 loss per share $0.23
March 1, 2017 / 9:26 PM / 9 months ago

BRIEF-Retrophin Q4 loss per share $0.23

March 2 (Reuters) - Retrophin Inc

* Retrophin inc says phase 3 trial of sparsentan in fsgs to initiate in second half of 2017

* Retrophin inc - phase 3 trial of sparsentan in fsgs to initiate in second half of 2017

* Retrophin inc - interim analysis of proteinuria to serve as basis for nda filing for accelerated approval

* Retrophin inc - net product sales for q4 of 2016 were $37.3 million, compared to net product sales of $30.4 million for same period in 2015

* Retrophin inc - company expects full year 2017 net product sales to be in range of $150.0 to $160.0 million

* Retrophin provides sparsentan regulatory update; reports fourth quarter and full year 2016 financial results

* Q4 loss per share $0.23

* Q4 adjusted non-gaap earnings per share $0.00

* Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below